WO2016009095A1 - Functional textile fabrics - Google Patents
Functional textile fabrics Download PDFInfo
- Publication number
- WO2016009095A1 WO2016009095A1 PCT/ES2015/070328 ES2015070328W WO2016009095A1 WO 2016009095 A1 WO2016009095 A1 WO 2016009095A1 ES 2015070328 W ES2015070328 W ES 2015070328W WO 2016009095 A1 WO2016009095 A1 WO 2016009095A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- endorphin
- textile
- textile fabric
- bioactive molecule
- fabric
- Prior art date
Links
- 239000004753 textile Substances 0.000 title claims abstract description 90
- 239000004744 fabric Substances 0.000 title claims abstract description 60
- 101800005049 Beta-endorphin Proteins 0.000 claims abstract description 42
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims abstract 15
- 230000000975 bioactive effect Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 14
- 229920000742 Cotton Polymers 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229920002994 synthetic fiber Polymers 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229920000297 Rayon Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 239000012209 synthetic fiber Substances 0.000 claims description 4
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 229920002334 Spandex Polymers 0.000 claims description 3
- 235000009120 camo Nutrition 0.000 claims description 3
- 235000005607 chanvre indien Nutrition 0.000 claims description 3
- 239000011487 hemp Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 239000002964 rayon Substances 0.000 claims description 3
- 210000002268 wool Anatomy 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 abstract description 20
- 230000036642 wellbeing Effects 0.000 abstract description 9
- 102400000748 Beta-endorphin Human genes 0.000 description 27
- 239000000463 material Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000002304 perfume Substances 0.000 description 8
- 108010049140 Endorphins Proteins 0.000 description 7
- 102000009025 Endorphins Human genes 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 239000002917 insecticide Substances 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229920001872 Spider silk Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- -1 yarn Substances 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- GEHMBYLTCISYNY-UHFFFAOYSA-N Ammonium sulfamate Chemical compound [NH4+].NS([O-])(=O)=O GEHMBYLTCISYNY-UHFFFAOYSA-N 0.000 description 1
- 229920002955 Art silk Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010016352 Feeling of relaxation Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 230000003763 resistance to breakage Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/01—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
- D06M15/15—Proteins or derivatives thereof
Definitions
- the present invention falls within the field of materials, in particular the field of textile fibers or materials, in particular the invention relates to those textile materials or textile fibers used for the manufacture of functional textile elements comprising at least one molecule.
- the present invention relates to a fabric made from textile fibers comprising at least one biologically active molecule, as well as to the textile garment made from said fabric.
- the present invention also relates to a process for the manufacture of textile fabrics object of the invention comprising the bioactive molecule.
- it refers to the application of at least one peptide, such as an opioid neurotransmitter of the endorphin type, in a cotton-based fabric, using a pipette with an optimized solution and concentration.
- the present invention also relates to the use of said textile fabrics to manufacture textile garments that produce in the individual that they carry a feeling of general well-being.
- the present invention thus provides a practical and simple solution that reports well-being in the users or patients who wear the garments as it had not been seen in the state of the art to date.
- the effects it produces in the users of these tissues, the application of these molecules consist in the deceleration of the growth of cancer cells, promote the feeling of well-being, increase relaxation and inhibit the pain, and on the other hand produce feelings of placidity, joy, pleasure, desire to live and good humor, about people who are in contact with the tissue in question.
- the procedures of ennoblement can be divided into purely mechanical and wet.
- the liquids used are mainly water and, to a lesser extent, solvents, as well as liquefied ammonia gas.
- Another important element is water vapor.
- a large number of chemical products, dyes and chemical auxiliary agents are used.
- ES2245795 discloses a composition
- a composition comprising a peptide or a deposition adjuvant protein with a high affinity with the fibers or a surface, and a functional agent bound / adsorbed to the peptide or the adjuvant protein of the deposition, wherein said deposition peptide or protein is cellulose or the binding domain thereof, and said functional agent is selected from a perfume, an encapsulated perfume, a photoprotective agent, a soil-releasing polymer, a dirt repellent agent, a compound Fabric softener, an insecticide, a fungicide, antioxidants or pigment fixatives.
- a functional agent in the context of this invention is a compound that provides a desirable effect for a fiber, fabric or surface not for the individual wearing it.
- patent ES2087996 discloses a method for applying an insecticide to a fibrous textile material, characterized by encapsulating the insecticide within microcapsules of a substance that is a food, to which insects or their larvae are attracted. , and joining the microcapsules to the fibers of the material by means of a binding agent that does not prevent the release of the insecticide when the microcapsules are devoured.
- composition comprises a polymer consisting of polyethyleneimine, a neutralizer of the bad smell consisting of an aliphatic aldehyde and an aqueous carrier, wherein said composition is practically free of any material that could dirty or stain fabrics.
- US2008175991 discloses a method of manufacturing a coated cellulose textile, whereby a silk peptide is polymerized as in a building block to develop a silk peptide / building nanoparticle block, said nanoparticles are then used to cover the textile.
- the resulting textile exhibits a high level of wrinkle recovery angle and / or resistance to breakage, all without the use of N-methylol compounds, including ureas and formaldehydes. In this case the advantage is over the fabric again.
- WO2012131745 discloses a binder (which comprises sulfamic acid, ammonium sulfamate and ammonium sulfate) and the production process of fabrics containing cyclodextrins fixed with the binder. More precisely, the present invention makes it possible to fix a binder to natural, synthetic or artificial fibers, and by means of thermal processes fix cyclodextrins with the same binder, giving rise to suitable tissues to incorporate active ingredients and to free them in time. Peculiar characteristics of said binder are its abilities to interact with various types of tissues, regardless of their composition, and with several types of cyclodextrin.
- This patent application discloses a method for treating spider silk filament, for use as a thread or composition in the manufacture of cosmetics, medical elements, textiles, and industrial applications, where the spider silk filament, from genetically modified organisms, it is treated with at least one component selected from the group consisting of vitamins, hormones, antioxidants, chelating agents, antibiotics, preservatives, fragrances, dyes, pigments, magnetic nanoparticles, nanocrystals, adhesion enhancers cellular, thermal insulators, shrinkage agents and cosmetic, medical or dermatological active substances. Fabrics obtained by this method are stronger, biocompatible, biodegradable and have superior thermal conductivity.
- the treated spider silk filament can also be applied in an oil-petticoat or water-in-oil protective cream that is hypoallergenic and ensures firmer skin, but has no effect directly on the skin from the woven garment.
- JPH09158041 discloses a method of obtaining clothing, such as underwear sufficiently capable of masking body odor due to perspiration, etc., without imparting an unpleasant sensation to a user by impregnating the clothing with a perfume precursor capable of producing a perfume component by hydrolysis.
- the solution proposed by this patent is that the functional clothing is obtained by impregnating a fibrous material or a knitted fabric that constitutes the clothing with a perfume precursor such as a glycoside of a perfume, a glyceride or a peptide derivative.
- the perfume precursor is preferably impregnated in an amount of 0.01-20% by weight.
- the clothing or the fibrous material can be impregnated even with an enzyme capable of breaking down the perfume precursor to regulate the amount of an aroma released.
- KR20040063730 Another patent of the next state of the art is KR20040063730.
- This patent application discloses a functional textile that contains functional medical materials that are characterized by stimulating the immune system and the lymphatic system to control functions of vital importance, which has anti-cancer property, for disease prevention, which has the function of disease recovery, vital rhythm control, prevent aging and increased autoimmunity.
- the functional medical materials are ribonucleic acid, oligosaccharides, chitosan, polysaccharide, amino acid, oligopeptides, peptideglycans, probiotics of useful microorganisms, functional plants and an algae extract.
- patent KR20040064170 The last patent detected by the researchers of the present invention is patent KR20040064170.
- This patent application is related to the previous one and discloses a functional cotton that contains functional medical materials and is characterized by stimulating the immune system and the lymphatic system to control the function of vital importance, which has anti-cancer property, disease prevention , which has the function of disease recovery, vital rhythm control, preventing aging and increasing autoimmunity.
- Functional medical materials are ribonucleic acid, oligosaccharides, chitosan, polysaccharide, amino acid, oligopeptides, peptidoglycans, probiotics of useful microorganisms, functional plants and an algae extract.
- Figure 1. Shows a mass spectrum in which a defined peak is reflected in a range between 3464-3465 Daltons characteristic of ⁇ -endorphin that allows it to be used as a control measure to track the presence of the compound in the tissue in the following days.
- Figure 2. Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2 ⁇ g / ⁇ l of B-endorphin are reflected, after 6h of exposure to controlled room temperature ( ⁇ 22.5 ⁇ c).
- the tissue sample was treated as follows: Extraction by incubation with ACN: H 2 0 (1: 1) for 30 minutes at a controlled temperature of 22.52C. After incubation, it has been dried in a centrifugal desiccator, and the sample has been resuspended in 30 ⁇ . TFA 0.1% in water. The sample has been analyzed by splashing after desalting by R2R3 column (reverse phase, similar to C18 / C8).
- Figure 4. Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2 ⁇ g / ⁇ l of B-endorphin are reflected, after 48h of exposure to controlled room temperature ( ⁇ 22.5 ⁇ c). The tissue sample was treated in the same manner as Figure 2.
- Figure 5. Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2 ⁇ g / ⁇ l of B-endorphin are reflected, after 72h of exposure to controlled room temperature ( ⁇ 22.5 ⁇ c). The tissue sample was treated in the same manner as Figure 2.
- Figure 6. Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2 ⁇ g / ⁇ l of B-endorphin are reflected, after 10 days of exposure to controlled room temperature ( ⁇ 22.5 ⁇ c). The tissue sample was treated in the same manner as Figure 2.
- textile fibers are understood regardless of the set of filaments or strands that can be used to form threads and with them fabrics, either by spinning or by other physical or chemical processes.
- textile fibers are the basic structures of textile fabrics.
- Textile fiber is considered any material whose length is much greater than its diameter and which can be spun.
- textile fabric is considered to be the fabric made from textile fibers, that is, the textile product as a result of weaving textile threads, filaments or fibers.
- textile garment is considered to be any final material obtained from the textile fabric object of the present invention that will be placed in contact with the user's skin.
- bioactive molecule is considered to be any compound, molecular entity, ingredient or active agent whatever its origin - human, animal, vegetable, chemical or other - to which an appropriate activity beneficial to health is attributed and / or promote the feeling of well-being, increase relaxation and inhibit pain or produce feelings of placidity.
- the invention relates to those textile materials or textile fibers used for the manufacture of functional textile fabrics comprising at least one biologically active molecule.
- the biologically active molecule incorporated in the textile tissue is preferably a peptide, such as an opioid neurotransmitter of the endorphin type. More preferably ⁇ -endorphin.
- Beta endorphin is an endogenous opioid hormone and neurotransmitter that is produced in the central nervous system. It acts primarily as a moderator of pain, reducing the transmission and effectiveness of sensory stimuli. Its receptors are located along the central and peripheral nervous system and are called opioid receptors, specifically ⁇ receptors. When the neurotransmitter is attached to the receptor it causes Supra peripheral spinal analgesia that results, among other effects, in a dilation of blood vessels, euphoria and sedation. It has great influence on the immune system. Leukocytes are extremely sensitive to endorphins, for which they have specific receptors. Endorphins increase the production and efficacy of T cells, which keep viruses, bacteria and cancer cells at bay and also stimulate the synthesis of endogenous antioxidants.
- the present invention relates to a fabric made from textile fibers comprising at least one biologically active molecule, as well as to the textile garment made from said fabric.
- the present invention also relates to a process for the manufacture of textile fabrics object of the invention comprising the bioactive molecule.
- it refers to the application of at least one peptide, such as an opioid neurotransmitter of the endorphin type, in a cotton-based fabric, using a pipette with an optimized solution and concentration.
- the present invention also relates to the use of said textile fabrics to manufacture textile garments that produce in the individual that they carry a feeling of general well-being.
- the present invention therefore provides a practical and simple solution that reports well-being in the users or patients wearing the garments made from the tissue impregnated with a concentration of Beta endorphins.
- the effects it produces on the users of these tissues, the application of these molecules consist of the slowdown of the growth of cancer cells, promote the feeling of well-being, increase relaxation and inhibit pain, and on the other hand produce feelings of placidity, joy , pleasure, desire to live and good humor, about people who are in contact with the tissue in question.
- the concentration of ⁇ -endorphin is 0.1 to 500 ⁇ g / ⁇ L in H 2 0 and preferably 2 ⁇ g / ⁇ L of ⁇ -endorphin in H 2 0. This concentration is easily detected by a MALDI spectrometer. TOF Bruker Autoflex III Smartbeam, so that it can be verified that the textile fabric effectively comprises endorphin.
- a textile fabric comprising a composition of at least one bioactive molecule that is ⁇ -endorphin in which the composition of the bioactive molecule is from 0.1 to 500 ⁇ g / ⁇ L of ⁇ -endorphin in H 2 0 and preferably 2 ⁇ g / ⁇ L of ⁇ -endorphin in H 2 0.
- the textile fabric is a natural textile fabric selected from the group consisting of cotton, wool, silk, linen, hemp or biso, or artificial textile fabric selected from the group consisting of polyester, nylon, rayon, elastane, Taffeta or gauze.
- the textile fabric is cotton.
- the textile fabric of step a.-) is a natural textile fabric selected from the group consisting of cotton, wool, silk, linen, hemp or biso, or artificial textile fabric selected from the group consisting of polyester, nylon, rayon, elastane, taffeta or gauze.
- the textile fabric is cotton.
- the application of step b.-) is carried out with a device selected from the group consisting of pipette, swab, dropper, etc.
- it is done with an automatic pipette, with solid phase extraction by means of reverse-phase Zip-Tip ® tips.
- the application occurs directly in the fabric, so that it is absorbed by the tissue, the molecule being attached to the fibers of the textile fabric itself.
- the process object of the present invention is characterized in that the addition of ⁇ -endorphin from step b.-) is carried out with an automatic pipette.
- the process object of the present invention is characterized in that the addition of ⁇ -endorphin of step b.-) is carried out by atomizing a solution with the bioactive molecule on the tissue, waiting a few minutes to its absorption
- ⁇ -endorphin from step b.- is performed at a concentration of 2ug ⁇ ⁇ -endorphin L H 2 0.
- Another aspect of the present invention is a textile garment suitable for absorbing and releasing a bioactive molecule of the ⁇ -endorphin type that is obtained by the process of the present invention.
- the aforementioned textile garment is suitable for absorbing and releasing a bioactive molecule of the ⁇ -endorphin type and is selected from the group consisting of dressings, gauze, sheets and clothing.
- Another aspect of the present invention is the use of the textile fabric object of the present invention to manufacture a textile garment suitable for absorbing and releasing a bioactive molecule of the ⁇ -endorphin type.
- EXAMPLE 1 Test of adhesion or fixation of ⁇ -endorphin to textile fabric.
- the amount charged was 7 ⁇ , with elution in 0.5 ⁇ matrix (synapine acid, 10 mg / ml, in ACN: 0.1% TFA [70:30]).
Landscapes
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
Abstract
The present invention relates to a textile fabric made from textile fibers which comprises at least one biologically active molecule which is β-endorphin. The present invention also relates to a method for manufacturing the textile fabrics which are the object of the invention which comprise β-endorphin. The present invention also relates to the use of said textile fabrics for manufacturing textile garments which produce a feeling of general well-being in the individuals who wear them.
Description
TEJIDOS TEXTILES FUNCIONALES FUNCTIONAL TEXTILE FABRICS
D E S C R I P C I O N OBJETO Y CAMPO DE LA INVENCIÓN D E S C R I P C I O N OBJECT AND FIELD OF THE INVENTION
La presente invención se enmarca dentro del campo de los materiales, en concreto al campo de las fibras o materiales textiles, en particular la invención se refiere a aquellos materiales textiles o fibras textiles utilizados para la fabricación de elementos textiles funcionales que comprenden al menos una molécula biológicamente activa. The present invention falls within the field of materials, in particular the field of textile fibers or materials, in particular the invention relates to those textile materials or textile fibers used for the manufacture of functional textile elements comprising at least one molecule. biologically active
La presente invención se refiere a un tejido confeccionado a partir de fibras textiles que comprenden al menos una molécula biológicamente activa, así como a la prenda textil confeccionada a partir de dicho tejido. The present invention relates to a fabric made from textile fibers comprising at least one biologically active molecule, as well as to the textile garment made from said fabric.
La presente invención también se refiere a un procedimiento para la fabricación de los tejidos textiles objeto de la invención que comprenden la molécula bioactiva. En particular se refiere a la aplicación de al menos un péptido, como un neurotransmisor opiáceo del tipo endorfina, en un tejido de base algodón, utilizando para ello una pipeta con una disolución y concentración optimizada. The present invention also relates to a process for the manufacture of textile fabrics object of the invention comprising the bioactive molecule. In particular, it refers to the application of at least one peptide, such as an opioid neurotransmitter of the endorphin type, in a cotton-based fabric, using a pipette with an optimized solution and concentration.
La presente invención también se refiere al uso de dichos tejidos textiles para fabricar prendas textiles que producen en el individuo que las llevan una sensación de bienestar general. The present invention also relates to the use of said textile fabrics to manufacture textile garments that produce in the individual that they carry a feeling of general well-being.
La presente invención proporciona por tanto una solución práctica y sencilla que reporta bienestar en los usuarios o pacientes que llevan las prendas como no se había visto en el estado del arte hasta la fecha. Los efectos que produce en los usuarios de estos tejidos, la aplicación de dichas moléculas consisten en la desaceleración del crecimiento de células cancerígenas, promueven la sensación de bienestar, aumentan la relajación e inhiben el
dolor, y por otro lado producen sensaciones de placidez, alegría, placer, ganas de vivir y buen humor, sobre las personas que están en contacto con el tejido en cuestión. The present invention thus provides a practical and simple solution that reports well-being in the users or patients who wear the garments as it had not been seen in the state of the art to date. The effects it produces in the users of these tissues, the application of these molecules consist in the deceleration of the growth of cancer cells, promote the feeling of well-being, increase relaxation and inhibit the pain, and on the other hand produce feelings of placidity, joy, pleasure, desire to live and good humor, about people who are in contact with the tissue in question.
ANTECEDENTES DE LA INVENCIÓN BACKGROUND OF THE INVENTION
Bajo el concepto de empresa textil se engloba de un modo muy general un lugar de fabricación que trabaja con materiales hilables, como fibras, hilos, torzales, tejidos, géneros de mallas, telas no tejidas, fieltros, pieles sintéticas y artículos similares. La industria de la confección además se refiere a aquella que procesa la mayor parte de los productos de la industria textil para obtener elementos complejos confeccionados, como prendas de vestir por ejemplo. Under the concept of a textile company, a manufacturing site that works with spun materials, such as fibers, threads, torzales, fabrics, mesh fabrics, nonwoven fabrics, felts, synthetic skins and similar items, is included in a very general way. The garment industry also refers to the one that processes most of the products of the textile industry to obtain ready-made complex elements, such as clothing for example.
Originalmente, la industria textil sólo procesaba materias primas naturales de origen vegetal y animal. Sin embargo, la proporción de fibras artificiales -como fibras de celulosa regenerada, seda artificial, viscosa obtenida de la madera y de los residuos del algodón o fibras totalmente sintéticas, como poliamida, poliacrilamida y poliéster (provenientes todas ellas del petróleo)- en la demanda global de fibras sigue creciendo en todo el mundo. Así en los años noventa, la industria de fibras sintéticas cubrió aproximadamente el 45% de la demanda mundial de fibras textiles, representando un volumen de 42,9 millones de toneladas. Originally, the textile industry only processed natural raw materials of plant and animal origin. However, the proportion of artificial fibers - such as regenerated cellulose fibers, artificial silk, viscose obtained from wood and cotton residues or fully synthetic fibers, such as polyamide, polyacrylamide and polyester (all from petroleum) - in the Global fiber demand continues to grow worldwide. Thus, in the 1990s, the synthetic fiber industry covered approximately 45% of the world demand for textile fibers, representing a volume of 42.9 million tons.
En estos últimos años la industria textil se ha centrado fundamentalmente en la obtención de nuevos materiales tejidos o no tejidos de valor añadido para los usuarios, así como en el empleo de diferentes fibras artificiales y mezclas de éstas para obtención de materiales finales tecnológicamente diferentes. In recent years the textile industry has focused mainly on obtaining new woven or non-woven materials of added value for users, as well as the use of different artificial fibers and mixtures of these to obtain technologically different final materials.
Sin embargo, hay una de las etapas que forman parte del proceso de obtención de tejidos textiles que está cobrando cada vez mayor importancia y que se denomina proceso de ennoblecimiento textil.
Bajo el concepto ennoblecimiento textil se entiende el tratamiento textil adicional como blanqueo, tinte, estampado y acabado de los productos textiles en las diversas fases de su procesamiento (fibra, hilo, tejido, género de punto por urdimbre, género confeccionado). Con ello se intenta elevar la utilidad o de los productos y adaptarlos a las necesidades funcionales y a los requerimientos de la moda en constante evolución. However, there is one of the stages that are part of the process of obtaining textile fabrics that is becoming increasingly important and is called the textile ennoblement process. Under the concept of textile enrichment, additional textile treatment is understood as bleaching, dyeing, stamping and finishing of textile products in the various phases of their processing (fiber, yarn, fabric, warp knitwear, ready made gender). This attempts to raise the utility or products and adapt them to the functional needs and the requirements of the constantly evolving fashion.
Los procedimientos de ennoblecimiento se pueden dividir en meramente mecánicos y en húmedos. Los líquidos que se utilizan son principalmente el agua y, en menor medida, los disolventes, así como gas de amoníaco licuado. Otro elemento importante es el vapor de agua. Para lograr los efectos deseados se utiliza un gran número de productos químicos, colorantes y agentes auxiliares químicos. The procedures of ennoblement can be divided into purely mechanical and wet. The liquids used are mainly water and, to a lesser extent, solvents, as well as liquefied ammonia gas. Another important element is water vapor. To achieve the desired effects, a large number of chemical products, dyes and chemical auxiliary agents are used.
Sin embargo, este procedimiento de ennoblecimiento textil raras veces se ha centrado en la adición de sustancias biológicamente activas, como las del objeto de la presente invención. Por ello, la presente invención constituye una diferencia sustancial respecto del estado de la técnica. However, this textile enrichment process has rarely focused on the addition of biologically active substances, such as those of the object of the present invention. Therefore, the present invention constitutes a substantial difference from the prior art.
En relación con estas premisas anteriormente citadas en el estado de la técnica, hay diferentes patentes que describen y protegen varios métodos para la fabricación de materiales textiles funcionales, pero diferentes al desarrollado por los investigadores de la presente invención. In relation to these premises previously cited in the state of the art, there are different patents that describe and protect various methods for manufacturing functional textile materials, but different from those developed by the researchers of the present invention.
De este modo, podemos encontrar el documento ES2245795 que divulga una composición que comprende un péptido o una proteína coadyuvante de la deposición con una elevada afinidad con las fibras o una superficie, y a un agente funcional unido/adsorbido al péptido o a la proteína coadyuvante de la deposición, en la que dicho péptido o proteína coadyuvante de la deposición es celulosa o el dominio de unión de la misma, y dicho agente funcional se selecciona entre un perfume, un perfume encapsulado, un agente fotoprotector, un polímero liberador de la suciedad, un agente repelente de la suciedad, un compuesto
suavizante de telas, un insecticida, un fungicida, antioxidantes o activos fijadores de pigmentos. Un agente funcional en el contexto de esta invención es un compuesto que proporciona un efecto deseable para una fibra, tela o superficie no para el individuo que lo lleva. Thus, we can find the document ES2245795 which discloses a composition comprising a peptide or a deposition adjuvant protein with a high affinity with the fibers or a surface, and a functional agent bound / adsorbed to the peptide or the adjuvant protein of the deposition, wherein said deposition peptide or protein is cellulose or the binding domain thereof, and said functional agent is selected from a perfume, an encapsulated perfume, a photoprotective agent, a soil-releasing polymer, a dirt repellent agent, a compound Fabric softener, an insecticide, a fungicide, antioxidants or pigment fixatives. A functional agent in the context of this invention is a compound that provides a desirable effect for a fiber, fabric or surface not for the individual wearing it.
Otro documento del estado del arte es la patente ES2087996 que divulga un método para aplicar un insecticida a un material textil fibroso, caracterizado por encapsular el insecticida dentro de microcápsulas de una sustancia que es un alimento, a la cual son atraídos los insectos o sus larvas, y unir las microcápsulas a las fibras del material mediante un agente de unión que no impide la liberación del insecticida cuando son devoradas las microcápsulas. Another document of the state of the art is patent ES2087996 which discloses a method for applying an insecticide to a fibrous textile material, characterized by encapsulating the insecticide within microcapsules of a substance that is a food, to which insects or their larvae are attracted. , and joining the microcapsules to the fibers of the material by means of a binding agent that does not prevent the release of the insecticide when the microcapsules are devoured.
Otro documento publicado es la patente MX2012003293 que divulga una composición refrescante para reducir el mal olor, donde la composición comprende un polímero que consiste en polietilenimina, un neutralizador del mal olor que consiste en un aldehido alifático y un portador acuoso, en donde dicha composición está prácticamente libre de cualquier material que pudiera ensuciar o manchar las telas. Another document published is the patent MX2012003293 which discloses a refreshing composition to reduce the bad smell, where the composition comprises a polymer consisting of polyethyleneimine, a neutralizer of the bad smell consisting of an aliphatic aldehyde and an aqueous carrier, wherein said composition is practically free of any material that could dirty or stain fabrics.
La patente US2008175991 divulga un método de fabricación de un textil de celulosa recubierto, por el que un péptido de seda se polimeriza como en un bloque de construcción para desarrollar un péptido de seda / bloque de nanopartículas de construcción, dichas nanopartículas a continuación se utilizan para recubrir el textil. El textil resultante exhibe un alto nivel de ángulo de recuperación de arrugas y / o resistencia a la rotura, todo sin el uso de compuestos de N-metilol, incluyendo ureas y formaldehidos. En este caso la ventaja redunda sobre el tejido nuevamente. US2008175991 discloses a method of manufacturing a coated cellulose textile, whereby a silk peptide is polymerized as in a building block to develop a silk peptide / building nanoparticle block, said nanoparticles are then used to cover the textile. The resulting textile exhibits a high level of wrinkle recovery angle and / or resistance to breakage, all without the use of N-methylol compounds, including ureas and formaldehydes. In this case the advantage is over the fabric again.
Por otro lado encontramos la solicitud de patente WO2012131745 que divulga un aglutinante (que comprende ácido sulfámico, sulfamato de amonio y sulfato de amonio) y el proceso de producción de telas que contienen ciclodextrinas fijados con el aglutinante. Más precisamente, la presente invención permite fijar un aglutinante a las fibras naturales, sintéticas o artificiales, y por medio de los procesos térmicos fijar ciclodextrinas con el mismo aglutinante, dando lugar a los tejidos adecuados para incorporar principios activos y
para liberarlos en el tiempo. Características peculiares de dicho aglutinante son sus capacidades para interactuar con varios tipos de tejidos, independientemente de su composición, y con varios tipos de ciclodextrina. Otras peculiaridades de la invención son: la capacidad de producir telas funcionalizadas, adaptados para ser modificadas con las moléculas deseadas y para liberarlas gradualmente a lo largo de tiempo, con un proceso que no altera las características originales de dicha tela; la posibilidad de repetir varias veces la unión de tales moléculas, con el fin de ser capaz de definir dichos tejidos como " recargables". Otra solicitud del estado de la técnica es la patente US20052600905 que divulga un material textil con una ciclodextrina que tiene una matriz polimérica que contiene ciclodextrina y / o un derivado de ciclodextrina, así como un método para la fabricación de un material de este tipo textil. Otra solicitud del estado del arte del tratamiento de tejidos es la solicitud WO2013147590. Esta solicitud de patente divulga un método para el tratamiento del filamento de seda de araña, para su uso como un hilo o composición en la fabricación de cosméticos, elementos médicos, textiles, y aplicaciones industriales, en donde el filamento de la seda de araña, proveniente de organismos modificados genéticamente, se trata con al menos un componente seleccionado de entre el grupo que consiste en vitaminas, hormonas, antioxidantes, agentes quelantes, antibióticos, agentes conservantes, fragancias, colorantes, pigmentos, nanopartículas magnéticas, nanocristales, potenciadores de la adhesión celular, aislantes térmicos, agentes de contracción y sustancias activas cosméticas, médicas o dermatológicas. Tejidos obtenidos por este método son más fuertes, biocompatibles, biodegradables y tienen una conductividad térmica superior. El filamento tratado de seda de araña también se puede aplicar en una crema protectora de aceite-enagua o agua-en-aceite que es hipoalergénico y asegura una piel más firme, pero no tiene efecto directamente sobre la piel desde la prenda tejida.
La patente JPH09158041 divulga un método para obtener ropa, como ropa interior suficientemente capaz de enmascarar el olor corporal debido a la transpiración, etc., sin impartir una sensación desagradable para un usuario mediante la impregnación de la ropa con un precursor de perfume capaz de producir un componente de perfume por hidrólisis. La solución planteada por esta patente es que la ropa funcional se obtiene mediante la impregnación de un material fibroso o un tejido de punto que constituye la ropa con un precursor de perfume tal como un glicósido de un perfume, un glicérido o un derivado de péptido. El precursor de perfume se impregna preferiblemente en una cantidad de 0,01- 20% en peso. La ropa o el material fibroso se pueden impregnar incluso con una enzima capaz de descomponer el precursor de perfume para regular la cantidad de un aroma liberado. On the other hand we find the patent application WO2012131745 which discloses a binder (which comprises sulfamic acid, ammonium sulfamate and ammonium sulfate) and the production process of fabrics containing cyclodextrins fixed with the binder. More precisely, the present invention makes it possible to fix a binder to natural, synthetic or artificial fibers, and by means of thermal processes fix cyclodextrins with the same binder, giving rise to suitable tissues to incorporate active ingredients and to free them in time. Peculiar characteristics of said binder are its abilities to interact with various types of tissues, regardless of their composition, and with several types of cyclodextrin. Other peculiarities of the invention are: the ability to produce functionalized fabrics, adapted to be modified with the desired molecules and to gradually release them over time, with a process that does not alter the original characteristics of said fabric; the possibility of repeating the binding of such molecules several times, in order to be able to define said tissues as "rechargeable". Another application of the prior art is US20052600905 which discloses a textile material with a cyclodextrin having a polymeric matrix containing cyclodextrin and / or a cyclodextrin derivative, as well as a method for manufacturing a material of this textile type. Another application of the state of the art of tissue treatment is the application WO2013147590. This patent application discloses a method for treating spider silk filament, for use as a thread or composition in the manufacture of cosmetics, medical elements, textiles, and industrial applications, where the spider silk filament, from genetically modified organisms, it is treated with at least one component selected from the group consisting of vitamins, hormones, antioxidants, chelating agents, antibiotics, preservatives, fragrances, dyes, pigments, magnetic nanoparticles, nanocrystals, adhesion enhancers cellular, thermal insulators, shrinkage agents and cosmetic, medical or dermatological active substances. Fabrics obtained by this method are stronger, biocompatible, biodegradable and have superior thermal conductivity. The treated spider silk filament can also be applied in an oil-petticoat or water-in-oil protective cream that is hypoallergenic and ensures firmer skin, but has no effect directly on the skin from the woven garment. JPH09158041 discloses a method of obtaining clothing, such as underwear sufficiently capable of masking body odor due to perspiration, etc., without imparting an unpleasant sensation to a user by impregnating the clothing with a perfume precursor capable of producing a perfume component by hydrolysis. The solution proposed by this patent is that the functional clothing is obtained by impregnating a fibrous material or a knitted fabric that constitutes the clothing with a perfume precursor such as a glycoside of a perfume, a glyceride or a peptide derivative. The perfume precursor is preferably impregnated in an amount of 0.01-20% by weight. The clothing or the fibrous material can be impregnated even with an enzyme capable of breaking down the perfume precursor to regulate the amount of an aroma released.
Otra patente del estado del arte próximo es KR20040063730. Esta solitud de patente divulga un textil funcional que contiene materiales médicos funcionales que se caracterizan por estimular el sistema inmunológico y el sistema linfático para controlar funciones de importancia vital, que tiene propiedad anti-cáncer, para la prevención de enfermedades, que tiene la función de recuperación de la enfermedad, el control de ritmo vital, prevenir el envejecimiento y el aumento de la autoinmunidad. Los materiales médicos funcionales son el ácido ribonucleico, oligosacáridos, quitosano, polisacárido, aminoácido, oligopéptidos, péptidoglicanos, los probióticos de microorganismos útiles, plantas funcionales y un extracto de algas. Another patent of the next state of the art is KR20040063730. This patent application discloses a functional textile that contains functional medical materials that are characterized by stimulating the immune system and the lymphatic system to control functions of vital importance, which has anti-cancer property, for disease prevention, which has the function of disease recovery, vital rhythm control, prevent aging and increased autoimmunity. The functional medical materials are ribonucleic acid, oligosaccharides, chitosan, polysaccharide, amino acid, oligopeptides, peptideglycans, probiotics of useful microorganisms, functional plants and an algae extract.
La última patente detectada por los investigadores de la presente invención es la patente KR20040064170. Esta solicitud de patente está relacionada con la anterior y divulga un algodón funcional que contiene materiales médicos funcionales y se caracteriza por estimular el sistema inmunológico y el sistema linfático para controlar la función de vital importancia, que tiene propiedad anti-cáncer, la prevención de enfermedades, que tiene la función de recuperación de la enfermedad, el control de ritmo vital, prevenir el envejecimiento y el aumento de la autoinmunidad. Los materiales médicos funcionales son el ácido ribonucleico, oligosacáridos, quitosano, polisacárido, aminoácido, oligopéptidos,
péptidoglicanos, los probióticos de microorganismos útiles, plantas funcionales y un extracto de algas. The last patent detected by the researchers of the present invention is patent KR20040064170. This patent application is related to the previous one and discloses a functional cotton that contains functional medical materials and is characterized by stimulating the immune system and the lymphatic system to control the function of vital importance, which has anti-cancer property, disease prevention , which has the function of disease recovery, vital rhythm control, preventing aging and increasing autoimmunity. Functional medical materials are ribonucleic acid, oligosaccharides, chitosan, polysaccharide, amino acid, oligopeptides, peptidoglycans, probiotics of useful microorganisms, functional plants and an algae extract.
A partir del estado de la técnica encontrado, se observa que la adición de compuestos biológicamente activos como los del objeto de la presente invención no están descritos en el estado de la técnica, si bien sí se describe la posibilidad de incluir moléculas bioactivas en tejidos textiles. From the state of the art found, it is observed that the addition of biologically active compounds such as those of the object of the present invention are not described in the state of the art, although the possibility of including bioactive molecules in textile tissues is described .
BREVE DESCRIPCIÓN DE LAS FIGURAS BRIEF DESCRIPTION OF THE FIGURES
Para complementar la descripción que se está realizando y con objeto de ayudar a una mejor comprensión de las características de la invención, de acuerdo con un ejemplo preferente de realización práctica del mismo, se acompañan como parte integrante de dicha descripción, las siguientes figuras en donde con carácter ilustrativo y no limitativo, se ha representado lo siguiente: To complement the description that is being made and in order to help a better understanding of the features of the invention, according to a preferred example of practical realization thereof, the following figures are attached as an integral part of said description. In an illustrative and non-limiting manner, the following has been represented:
Figura 1.- Muestra un espectro de masas en donde se refleja un pico definido en un intervalo entre 3464-3465 Daltons característico de β-endorfina que permite utilizarlo como medida de control para rastrear en los días posteriores la presencia del compuesto en el tejido. Figure 1.- Shows a mass spectrum in which a defined peak is reflected in a range between 3464-3465 Daltons characteristic of β-endorphin that allows it to be used as a control measure to track the presence of the compound in the tissue in the following days.
Figura 2.- Muestra un espectro de masas en donde se reflejan triplicas de muestra de tejido de 1 cm2 embebido con 2μg/μl de B-endorfina, tras 6h de exposición a temperatura ambiente controlada (~22.5 ^c). La muestra de tejido se trató te la siguiente manera: Extracción por incubación con ACN:H20 (1:1) durante 30 minutos a temperatura controlada de 22.52C. Tras la incubación se ha procedido a desecado en desecador centrífugo, y se ha resuspendido la muestra en 30 μΙ. TFA 0.1% en agua. La muestra se ha analizado mediante spoteo tras desalado por columna R2R3 (fase reversa, similar a C18/C8). La cantidad cargada fueron 7μΙ, con elución en 0.5 μΙ de matriz (ácido sinapínico, 10 mg/ml, en ACN:TFA 0.1% [70:30]). Medición en un MALDI-TOF Bruker Autoflex III Smartbeam con detección en modo lineal.
Figura 3.- Muestra un espectro de masas en donde se reflejan triplicas de muestra de tejido de 1 cm2 embebido con 2μg/μl de B-endorfina, tras 24h de exposición a temperatura ambiente controlada (~22.5 ^c). La muestra de tejido se trató del mismo modo que la figura 2. Figure 2.- Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2μg / μl of B-endorphin are reflected, after 6h of exposure to controlled room temperature (~ 22.5 ^ c). The tissue sample was treated as follows: Extraction by incubation with ACN: H 2 0 (1: 1) for 30 minutes at a controlled temperature of 22.52C. After incubation, it has been dried in a centrifugal desiccator, and the sample has been resuspended in 30 μΙ. TFA 0.1% in water. The sample has been analyzed by splashing after desalting by R2R3 column (reverse phase, similar to C18 / C8). The amount charged was 7μΙ, with elution in 0.5 μΙ of matrix (synapine acid, 10 mg / ml, in ACN: 0.1% TFA [70:30]). Measurement on a MALDI-TOF Bruker Autoflex III Smartbeam with linear mode detection. Figure 3.- Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2μg / μl of B-endorphin are reflected, after 24h of exposure to controlled room temperature (~ 22.5 ^ c). The tissue sample was treated in the same manner as Figure 2.
Figura 4.- Muestra un espectro de masas en donde se reflejan triplicas de muestra de tejido de 1 cm2 embebido con 2μg/μl de B-endorfina, tras 48h de exposición a temperatura ambiente controlada (~22.5 ^c). La muestra de tejido se trató del mismo modo que la figura 2. Figure 4.- Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2μg / μl of B-endorphin are reflected, after 48h of exposure to controlled room temperature (~ 22.5 ^ c). The tissue sample was treated in the same manner as Figure 2.
Figura 5.- Muestra un espectro de masas en donde se reflejan triplicas de muestra de tejido de 1 cm2 embebido con 2μg/μl de B-endorfina, tras 72h de exposición a temperatura ambiente controlada (~22.5 ^c). La muestra de tejido se trató del mismo modo que la figura 2. Figure 5.- Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2μg / μl of B-endorphin are reflected, after 72h of exposure to controlled room temperature (~ 22.5 ^ c). The tissue sample was treated in the same manner as Figure 2.
Figura 6.- Muestra un espectro de masas en donde se reflejan triplicas de muestra de tejido de 1 cm2 embebido con 2μg/μl de B-endorfina, tras 10 días de exposición a temperatura ambiente controlada (~22.5 ^c). La muestra de tejido se trató del mismo modo que la figura 2. Figure 6.- Shows a mass spectrum in which triplicates of 1 cm 2 tissue sample embedded with 2μg / μl of B-endorphin are reflected, after 10 days of exposure to controlled room temperature (~ 22.5 ^ c). The tissue sample was treated in the same manner as Figure 2.
DESCRIPCIÓN DETALLADA DE LA INVENCIÓN DETAILED DESCRIPTION OF THE INVENTION
Para el objeto de la presente invención se entiende por "fibras textiles" o "materiales textiles" indistintamente al conjunto de filamentos o hebras susceptibles de ser usados para formar hilos y con ellos telas, bien sea mediante hilado o mediante otros procesos físicos o químicos. Así, las fibras textiles son las estructuras básicas de los tejidos textiles. Se considera fibra textil cualquier material cuya longitud sea muy superior a su diámetro y que pueda ser hilado.
Para el objeto de la presente invención se considera "tejido textil" al tejido confeccionado a partir de fibras textiles, es decir, al producto textil como resultado de tejer hilos, filamentos o fibras textiles. Para el objeto de la presente invención se considera "prenda textil" a cualquier material final obtenido a partir del tejido textil objeto de la presente invención que se colocará en contacto con la piel del usuario. Así puede ser desde un aposito fabricado a partir del tejido textil hasta una camiseta. Para el objeto de la presente invención se considera "molécula bioactiva", "compuestos bioactivo", "sustancia bioactiva", "compuesto biológicamente activo" ó "molécula biológicamente activa" a cualquier compuesto, entidad molecular, ingrediente o agente activo cualquiera que sea su origen -humano, animal, vegetal, químico o de otro tipo- a la que se atribuye una actividad apropiada beneficiosa para la salud y/o promueven la sensación de bienestar, aumentan la relajación e inhiben el dolor o producen sensaciones de placidez. For the purpose of the present invention, "textile fibers" or "textile materials" are understood regardless of the set of filaments or strands that can be used to form threads and with them fabrics, either by spinning or by other physical or chemical processes. Thus, textile fibers are the basic structures of textile fabrics. Textile fiber is considered any material whose length is much greater than its diameter and which can be spun. For the purpose of the present invention "textile fabric" is considered to be the fabric made from textile fibers, that is, the textile product as a result of weaving textile threads, filaments or fibers. For the purpose of the present invention, "textile garment" is considered to be any final material obtained from the textile fabric object of the present invention that will be placed in contact with the user's skin. So it can be from a dressing made from textile fabric to a shirt. For the purpose of the present invention, "bioactive molecule", "bioactive compound", "bioactive substance", "biologically active compound" or "biologically active molecule" is considered to be any compound, molecular entity, ingredient or active agent whatever its origin - human, animal, vegetable, chemical or other - to which an appropriate activity beneficial to health is attributed and / or promote the feeling of well-being, increase relaxation and inhibit pain or produce feelings of placidity.
En particular la invención se refiere a aquellos materiales textiles o fibras textiles utilizados para la fabricación de tejidos textiles funcionales que comprenden al menos una molécula biológicamente activa. In particular, the invention relates to those textile materials or textile fibers used for the manufacture of functional textile fabrics comprising at least one biologically active molecule.
En relación con el objeto de la presente invención, la molécula biológicamente activa incorporada en el tejido textil es de forma preferida un péptido, como un neurotrasmisor de tipo opiáceo del tipo endorfina. Más preferentemente β-endorfina. In relation to the object of the present invention, the biologically active molecule incorporated in the textile tissue is preferably a peptide, such as an opioid neurotransmitter of the endorphin type. More preferably β-endorphin.
Beta endorfina (β-endorfina) es un hormona y neurotransmisor endógeno opiáceo que se produce en el sistema nervioso central. Actúa principalmente como moderador de dolor, reduciendo la trasmisión y eficacia de estímulos sensoriales. Sus receptores están ubicados a lo largo del sistema nervioso central y periférico y son llamados receptores opiáceos, específicamente receptores μ. Al unirse el neurotransmisor al receptor ocasiona una
analgesia supra espinal periférica que resulta, entre otros efectos, en una dilatación de vasos sanguíneos, euforia y sedación. Tiene gran influencia sobre el sistema inmunitario. Los leucocitos son extremadamente sensibles a las endorfinas, para las cuales tienen receptores específicos. Las endorfinas aumentan la producción y eficacia de las células T, que mantienen a raya virus, bacterias y células cancerosas y también estimulan la síntesis de antioxidantes endógenos. Beta endorphin (β-endorphin) is an endogenous opioid hormone and neurotransmitter that is produced in the central nervous system. It acts primarily as a moderator of pain, reducing the transmission and effectiveness of sensory stimuli. Its receptors are located along the central and peripheral nervous system and are called opioid receptors, specifically μ receptors. When the neurotransmitter is attached to the receptor it causes Supra peripheral spinal analgesia that results, among other effects, in a dilation of blood vessels, euphoria and sedation. It has great influence on the immune system. Leukocytes are extremely sensitive to endorphins, for which they have specific receptors. Endorphins increase the production and efficacy of T cells, which keep viruses, bacteria and cancer cells at bay and also stimulate the synthesis of endogenous antioxidants.
La presente invención se refiere a un tejido confeccionado a partir de fibras textiles que comprenden al menos una molécula biológicamente activa, así como a la prenda textil confeccionada a partir de dicho tejido. The present invention relates to a fabric made from textile fibers comprising at least one biologically active molecule, as well as to the textile garment made from said fabric.
La presente invención también se refiere a un procedimiento para la fabricación de los tejidos textiles objeto de la invención que comprenden la molécula bioactiva. En particular se refiere a la aplicación de al menos un péptido, como un neurotrasmisor de tipo opiáceo del tipo endorfina, en un tejido de base algodón, utilizando para ello una pipeta con una disolución y concentración optimizada. The present invention also relates to a process for the manufacture of textile fabrics object of the invention comprising the bioactive molecule. In particular, it refers to the application of at least one peptide, such as an opioid neurotransmitter of the endorphin type, in a cotton-based fabric, using a pipette with an optimized solution and concentration.
La presente invención también se refiere al uso de dichos tejidos textiles para fabricar prendas textiles que producen en el individuo que las llevan una sensación de bienestar general. The present invention also relates to the use of said textile fabrics to manufacture textile garments that produce in the individual that they carry a feeling of general well-being.
La presente invención proporciona por tanto una solución práctica y sencilla que reporta bienestar en los usuarios o pacientes que llevan las prendas fabricadas a partir del tejido impregnado con una concentración de Beta endorfinas. Los efectos que produce en los usuarios de estos tejidos, la aplicación de dichas moléculas consisten en la desaceleración del crecimiento de células cancerígenas, promueven la sensación de bienestar, aumentan la relajación e inhiben el dolor, y por otro lado producen sensaciones de placidez, alegría, placer, ganas de vivir y buen humor, sobre las personas que están en contacto con el tejido en cuestión.
De forma preferida la concentración de β-endorfina, es de 0,1 a 500μg/μL en H20 y de forma preferente 2 μg/μL de β-endorfina en H20. Esta concentración es fácilmente detectada mediante un espectrómetro MALDI-TOF Bruker Autoflex III Smartbeam, de manera que se puede comprobar que efectivamente el tejido textil comprende la endorfina. The present invention therefore provides a practical and simple solution that reports well-being in the users or patients wearing the garments made from the tissue impregnated with a concentration of Beta endorphins. The effects it produces on the users of these tissues, the application of these molecules consist of the slowdown of the growth of cancer cells, promote the feeling of well-being, increase relaxation and inhibit pain, and on the other hand produce feelings of placidity, joy , pleasure, desire to live and good humor, about people who are in contact with the tissue in question. Preferably, the concentration of β-endorphin is 0.1 to 500μg / μL in H 2 0 and preferably 2 μg / μL of β-endorphin in H 2 0. This concentration is easily detected by a MALDI spectrometer. TOF Bruker Autoflex III Smartbeam, so that it can be verified that the textile fabric effectively comprises endorphin.
Es por tanto un objeto de la presente invención, un tejido textil que comprende una composición de al menos una molécula bioactiva que es β-endorfina en el que la composición de la molécula bioactiva es de 0,1 a 500μg/μL de β-endorfina en H20 y de forma preferente 2 μg/μL de β-endorfina en H20. It is therefore an object of the present invention, a textile fabric comprising a composition of at least one bioactive molecule that is β-endorphin in which the composition of the bioactive molecule is from 0.1 to 500μg / µL of β-endorphin in H 2 0 and preferably 2 μg / μL of β-endorphin in H 2 0.
Para el objeto de la presente invención, el tejido textil es un tejido textil natural seleccionado del grupo formado por algodón, lana, seda, lino, cáñamo o biso, o tejido textil artificial seleccionado del grupo formado por poliéster, nylon, rayón, elastano, tafetán o gasa. De forma preferente el tejido textil es de algodón. For the purpose of the present invention, the textile fabric is a natural textile fabric selected from the group consisting of cotton, wool, silk, linen, hemp or biso, or artificial textile fabric selected from the group consisting of polyester, nylon, rayon, elastane, Taffeta or gauze. Preferably, the textile fabric is cotton.
Es otro objeto de la presente invención, un procedimiento de obtención del tejido textil, en el que las etapas características son las siguientes: a. -) Tomar un tejido textil confeccionado con fibras naturales, sintéticas o mezcla de ambas, b. -) Aplicar una cantidad efectiva de al menos el compuesto bioactivo β-endorfina disuelta en agua, y c.-) dejar secar temperatura ambiente. It is another object of the present invention, a process for obtaining textile fabric, in which the characteristic steps are as follows: a. -) Take a textile fabric made with natural, synthetic fibers or a mixture of both, b. -) Apply an effective amount of at least the bioactive compound β-endorphin dissolved in water, and c.-) allow to dry at room temperature.
De forma preferida el tejido textil de la etapa a.-) es un tejido textil natural seleccionado del grupo formado por algodón, lana, seda, lino, cáñamo o biso, o tejido textil artificial seleccionado del grupo formado por poliéster, nylon, rayón, elastano, tafetán o gasa. De forma preferente el tejido textil es de algodón.
De forma preferida la aplicación de la etapa b.-) se realiza con un dispositivo seleccionado del grupo formado por pipeta, torunda, cuentagotas, etc. De forma preferida se hace con una pipeta automática, con extracción en fase solida mediante puntas tipo Zip-Tip® de fase reversa. Preferably, the textile fabric of step a.-) is a natural textile fabric selected from the group consisting of cotton, wool, silk, linen, hemp or biso, or artificial textile fabric selected from the group consisting of polyester, nylon, rayon, elastane, taffeta or gauze. Preferably, the textile fabric is cotton. Preferably, the application of step b.-) is carried out with a device selected from the group consisting of pipette, swab, dropper, etc. Preferably, it is done with an automatic pipette, with solid phase extraction by means of reverse-phase Zip-Tip ® tips.
La aplicación se da directamente en el tejido, de modo que es absorbido por el tejido, quedando la molécula unida a las fibras del propio tejido textil. The application occurs directly in the fabric, so that it is absorbed by the tissue, the molecule being attached to the fibers of the textile fabric itself.
De acuerdo con un aspecto importante el procedimiento objeto de la presente invención se caracteriza porque la adición de β-endorfina de la etapa b.-) se realiza con una pipeta automática. According to an important aspect, the process object of the present invention is characterized in that the addition of β-endorphin from step b.-) is carried out with an automatic pipette.
De acuerdo con un aspecto importante el procedimiento objeto de la presente invención se caracteriza porque la adición de β-endorfina de la etapa b.-) se realiza mediante atomización de una solución con la molécula bioactiva sobre el tejido, a la espera pocos minutos para su absorción. According to an important aspect, the process object of the present invention is characterized in that the addition of β-endorphin of step b.-) is carried out by atomizing a solution with the bioactive molecule on the tissue, waiting a few minutes to its absorption
De acuerdo con un aspecto importante el procedimiento objeto de la presente invención se caracteriza porque la adición de β-endorfina de la etapa b.-) se realiza en una concentración de 2ug^L de β-endorfina en H20. According to an important aspect of the process object of the present invention is characterized by the addition of β-endorphin from step b.-) is performed at a concentration of 2ug ^ β-endorphin L H 2 0.
Es otro aspecto de la presente invención una prenda textil adecuada para absorber y liberar una molécula bioactiva del tipo β-endorfina que se obtiene mediante el procedimiento de la presente invención. Another aspect of the present invention is a textile garment suitable for absorbing and releasing a bioactive molecule of the β-endorphin type that is obtained by the process of the present invention.
De acuerdo con otro aspecto, la prenda textil anteriormente citada es adecuada para absorber y liberar una molécula bioactiva del tipo β-endorfina y se selecciona del grupo formado por apositos, gasas, sabanas y prendas de vestir.
Es otro aspecto de la presente invención el uso del tejido textil objeto de la presente invención para fabricar una prenda textil adecuada para absorber y liberar una molécula bioactiva del tipo β-endorfina. EJEMPLOS DE REALIZACIÓN According to another aspect, the aforementioned textile garment is suitable for absorbing and releasing a bioactive molecule of the β-endorphin type and is selected from the group consisting of dressings, gauze, sheets and clothing. Another aspect of the present invention is the use of the textile fabric object of the present invention to manufacture a textile garment suitable for absorbing and releasing a bioactive molecule of the β-endorphin type. EXAMPLES OF REALIZATION
Los siguientes ejemplos específicos que se proporcionan aquí sirven para ilustrar la naturaleza de la presente invención. Estos ejemplos se incluyen solamente con fines ilustrativos y no han de ser interpretados como limitaciones a la invención que aquí se reivindica. The following specific examples provided herein serve to illustrate the nature of the present invention. These examples are included for illustrative purposes only and should not be construed as limitations on the invention claimed herein.
EJEMPLO 1: Prueba de adhesión o fijación de la β-endorfina al tejido textil. EXAMPLE 1: Test of adhesion or fixation of β-endorphin to textile fabric.
Las investigaciones de los inventores de la presente invención han demostrado la unión a las fibras de un tejido de algodón en un estudio realizado por espectrometría de masas. Para ello se incubaron las muestras a diferentes tiempos (1, 2, 3 y 10 días) a una temperatura media controlada de unos 22- 23^C. Tras la incubación se ha procedido a desecado en desecador centrífugo y se ha resuspendido la muestra en 30μί en ácido trifluoroacético (TFA) al 0.1% en agua. The investigations of the inventors of the present invention have demonstrated the binding to the fibers of a cotton fabric in a study conducted by mass spectrometry. For this, the samples were incubated at different times (1, 2, 3 and 10 days) at a controlled average temperature of about 22-23 ^ C. After the incubation, it was dried in a centrifugal desiccator and the sample was resuspended in 30μί in 0.1% trifluoroacetic acid (TFA) in water.
En este ensayo se demuestra con una técnica muy robusta que es la espectrometría de masas que la molécula permanece en el tejido de forma estable durante incluso varios días. This test demonstrates with a very robust technique that is the mass spectrometry that the molecule remains in the tissue stably for even several days.
Así observamos en el control positivo de la figura 1 que hay un pico definido a unos 3464- 3465 m/z (control) característico de β-endorfina que nos permite rastrear en los días posteriores la presencia del compuesto en el tejido. Thus we observe in the positive control of Figure 1 that there is a defined peak at about 3464-3465 m / z (control) characteristic of β-endorphin that allows us to track the presence of the compound in the tissue in the following days.
Así observamos cómo en triplicas de muestra de tejido de 1 cm2 embebido con 2μg/μl de β- endorfina, la presencia del compuesto bioactivo.
La medida se ha realizado con extracción por incubación con acetonitrilo en agua (ACN :H20) en un ratio 1:1 durante 30 minutos a temperatura controlada de 22.5^C. Tras la incubación se ha procedido a desecado en desecador centrífugo, y se ha resuspendido la muestra en 30μί en ácido trifluoroacético (TFA). La muestra se ha analizado mediante spoteo tras desalado por columna R2R3 (fase reversa, similar a C18/C8). La cantidad cargada fueron 7 μί, con elución en 0.5 μί de matriz (ácido sinapínico, 10 mg/ml, en ACN :TFA 0.1% [70:30]). Medición en un MALDI-TOF Bruker Autoflex II I Smartbeam con detección en modo lineal. Thus we observe how the presence of the bioactive compound in triplicates of 1 cm 2 tissue sample embedded with 2 μg / μl of β-endorphin. The measurement was carried out with extraction by incubation with acetonitrile in water (ACN: H 2 0) in a 1: 1 ratio for 30 minutes at a controlled temperature of 22.5 ^ C. After incubation, it has been dried in a centrifugal desiccator, and the sample has been resuspended in 30μί in trifluoroacetic acid (TFA). The sample has been analyzed by splashing after desalting by R2R3 column (reverse phase, similar to C18 / C8). The amount charged was 7 μί, with elution in 0.5 μί matrix (synapine acid, 10 mg / ml, in ACN: 0.1% TFA [70:30]). Measurement on a MALDI-TOF Bruker Autoflex II I Smartbeam with linear mode detection.
Así se observa cómo la β-endorfina sigue presente en el tejido textil tras 6 horas de exposición a temperatura ambiente controlada (~22.5 ^c) (ver figura 2), tras 24 horas de exposición a temperatura ambiente controlada (~22.5 ^c) (ver figura 3), tras 48 horas de exposición a temperatura ambiente controlada (~22.5 ^c) (ver figura 4), tras 72 horas de exposición a temperatura ambiente controlada (~22.5 ^c) (ver figura 5) y tras 10 días de exposición a temperatura ambiente controlada (~22.5 ^c) (ver figura 6). This shows how β-endorphin is still present in the textile fabric after 6 hours of exposure to controlled room temperature (~ 22.5 ^ c) (see figure 2), after 24 hours of exposure to controlled room temperature (~ 22.5 ^ c) (see figure 3), after 48 hours of exposure to controlled room temperature (~ 22.5 ^ c) (see figure 4), after 72 hours of exposure to controlled room temperature (~ 22.5 ^ c) (see figure 5) and after 10 days of exposure to controlled room temperature (~ 22.5 ^ c) (see figure 6).
Ejemplo 2: Prueba de eficacia Example 2: Efficacy Test
Una vez obtenida una muestra de camiseta de manga larga fabricada en algodón e impregnada en β-endorfina se probó en un paciente con dermatitis atópica en la zona de los brazos. La camiseta objeto de ensayo tenía β-endorfina en el brazo derecho y no en el izquierdo. El paciente tuvo puesta la camiseta por las noches durante un periodo de 5 días, notando sensación de bienestar y sensación de alivio en picor en el brazo que tenía impregnada la β-endorfina dando un grado de eficacia de 100%. Ejemplo 3: Prueba de eficacia Once a sample of long-sleeved T-shirt made of cotton and impregnated with β-endorphin was obtained, it was tested in a patient with atopic dermatitis in the arm area. The shirt under test had β-endorphin on the right arm and not on the left. The patient wore the shirt at night for a period of 5 days, noting a sense of well-being and a feeling of relief in itching in the arm that had the β-endorphin impregnated giving a 100% effectiveness. Example 3: Efficacy Test
Una vez obtenida una muestra de camiseta de manga corta fabricada en algodón e impregnada en β-endorfina se probó en una persona sana de 29 años. La camiseta objeto de ensayo tenía β-endorfina en ambos hombros. El voluntario tuvo puesta la camiseta por las mañanas durante un periodo de 3 días, notando de forma general una sensación de relax,
placer y felicidad, y un mayor nivel de energía que los días previos y posteriores al uso de camiseta impregnada con la β-endorfina, dando un grado de eficacia de 100%.
Once a sample of a short-sleeved T-shirt made of cotton and impregnated with β-endorphin was obtained, it was tested in a healthy person of 29 years. The shirt under test had β-endorphin on both shoulders. The volunteer wore the shirt in the mornings for a period of 3 days, generally noticing a feeling of relaxation, pleasure and happiness, and a higher level of energy than the days before and after the use of a shirt impregnated with β-endorphin, giving a degree of efficacy of 100%.
Claims
1. - Tejido textil caracterizado porque comprende una composición de al menos una molécula bioactiva que es β-endorfina. 1. - Textile fabric characterized in that it comprises a composition of at least one bioactive molecule that is β-endorphin.
2. - Tejido textil según la reivindicación 1 caracterizado porque la composición de la molécula bioactiva es de 0,1 a 500μg/μL de β-endorfina en H20. 2. - Woven textile according to claim 1 wherein the composition of the bioactive molecule is 0.1 to 500μg / uL of β-endorphin in H 2 0.
3. - Tejido textil según cualquiera de las reivindicaciones 1 a 2 caracterizado porque la composición de la molécula bioactiva es de 2μg/μL de β-endorfina en H20. 3. - Woven textile according to any of claims 1 to 2 wherein the composition of the bioactive molecule is 2μg / uL of β-endorphin in H 2 0.
4. - Procedimiento para la producción de un tejido textil adecuado para absorber y liberar una molécula bioactiva del tipo β-endorfina, caracterizado porque comprende las siguientes etapas: a. -) Tomar un tejido textil estándar confeccionado con fibras naturales, sintéticas o mezcla de ambas, b. -) Añadir una cantidad efectiva de al menos el compuesto bioactivo β-endorfina disuelta en agua, y c. -) dejar secar temperatura ambiente. 4. - Procedure for the production of a textile fabric suitable for absorbing and releasing a bioactive molecule of the β-endorphin type, characterized in that it comprises the following steps: a. -) Take a standard textile fabric made of natural, synthetic fibers or a mixture of both, b. -) Add an effective amount of at least the bioactive compound β-endorphin dissolved in water, and c. -) let dry at room temperature.
5. - Procedimiento según la reivindicación 4 caracterizado porque el tejido textil de la etapa a.-) es un tejido textil natural seleccionado del grupo formado por algodón, lana, seda, lino, cáñamo y biso. 5. - Method according to claim 4 characterized in that the textile fabric of step a.-) is a natural textile fabric selected from the group consisting of cotton, wool, silk, linen, hemp and biso.
6. - Procedimiento según la reivindicación 4 caracterizado porque el tejido textil de la etapa a.-) es un tejido textil artificial seleccionado del grupo formado por poliéster, nylon, rayón, elastano, tafetán y gasa.
6. - Method according to claim 4 characterized in that the textile fabric of step a.-) is an artificial textile fabric selected from the group consisting of polyester, nylon, rayon, elastane, taffeta and gauze.
7. - Procedimiento según la reivindicación 4 caracterizado porque la adición de β-endorfina de la etapa b.-) se realiza con un dispositivo seleccionado del grupo formado por pipeta, torunda y cuentagotas. 7. - Method according to claim 4 characterized in that the addition of β-endorphin of step b.-) is carried out with a device selected from the group consisting of pipette, swab and dropper.
8. - Procedimiento según la reivindicación 4 caracterizado porque la adición de β-endorfina de la etapa b.-) se realiza con una pipeta automática. 8. - Method according to claim 4 characterized in that the addition of β-endorphin of step b.-) is carried out with an automatic pipette.
9. - Procedimiento según la reivindicación 4 caracterizado porque la adición de β-endorfina de la etapa b.-) se realiza mediante atomización de una solución con la molécula bioactiva sobre el tejido, a la espera pocos minutos para su absorción. 9. - Method according to claim 4 characterized in that the addition of β-endorphin of step b.-) is carried out by atomizing a solution with the bioactive molecule on the tissue, waiting a few minutes for its absorption.
10. - Procedimiento según la reivindicación 4 caracterizado porque la adición de β-endorfina de la etapa b.-) se realiza en una concentración de 2ug^L de β-endorfina en H20. 10. - Method according to claim 4 characterized in that the addition of β-endorphin of step b.-) is carried out in a concentration of 2ug ^ L of β-endorphin in H 2 0.
11. - Prenda textil adecuada para absorber y liberar una molécula bioactiva del tipo β- endorfina, caracterizada porque se obtienen mediante el proceso de reivindicaciones 4 a 10. 11. - Textile garment suitable for absorbing and releasing a bioactive molecule of the β-endorphin type, characterized in that they are obtained by the process of claims 4 to 10.
12. - Prenda textil adecuada para absorber y liberar una molécula bioactiva del tipo β- endorfina según la reivindicación 11 caracterizada porque se selecciona del grupo formado por apositos, gasas, sabanas y prendas de vestir. 12. - Textile garment suitable for absorbing and releasing a bioactive molecule of the β-endorphin type according to claim 11 characterized in that it is selected from the group consisting of dressings, gauze, sheets and clothing.
13.- Uso del tejido textil para fabricar una prenda textil adecuada para absorber y liberar una molécula bioactiva del tipo β-endorfina.
13.- Use of textile fabric to manufacture a suitable textile garment to absorb and release a bioactive molecule of the β-endorphin type.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP201431073 | 2014-07-16 | ||
| ES201431073A ES2518765B2 (en) | 2014-07-16 | 2014-07-16 | Functional textile fabrics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016009095A1 true WO2016009095A1 (en) | 2016-01-21 |
Family
ID=51831085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/ES2015/070328 WO2016009095A1 (en) | 2014-07-16 | 2015-04-21 | Functional textile fabrics |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2518765B2 (en) |
| WO (1) | WO2016009095A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107641956A (en) * | 2017-09-08 | 2018-01-30 | 安徽龙盛纺织科技有限公司 | A kind of creped printing method of chiffon fabric |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019087124A1 (en) * | 2017-11-01 | 2019-05-09 | Clexio Biosciences Ltd. | Finished fibrous structures and methods of their use and preparation |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2005260A (en) | 1932-12-30 | 1935-06-18 | Atlas Powder Co | Press mechanism |
| ES2087996T3 (en) | 1990-01-18 | 1996-08-01 | Cpc International Inc | TEXTILE MATERIALS TREATMENT. |
| WO2003103550A2 (en) * | 2002-06-08 | 2003-12-18 | Ian Robert Thomson | Delivery system for a medicament or well-being enhancing composition |
| KR20040063730A (en) | 2003-01-08 | 2004-07-14 | 손영석 | Functional textile |
| KR20040064170A (en) | 2003-01-09 | 2004-07-16 | 손영석 | Functional cotton |
| EP1498113A1 (en) * | 2003-07-17 | 2005-01-19 | L'oreal | Use of beta-endorphin and/or agents with beta-endorphin-like activity in cosmetic and dermotology |
| DE10329685A1 (en) * | 2003-07-02 | 2005-01-20 | Cognis Deutschland Gmbh & Co. Kg | Microcapsules for use in detergents, rinsing or cleansing compositions or in production of pharmaceuticals, cosmetics or food supplements contain neurotransmitters or their precursors |
| ES2245795T3 (en) | 1996-07-01 | 2006-01-16 | Unilever N.V. | DETERGENT COMPOSITION. |
| US20080175991A1 (en) | 2007-01-22 | 2008-07-24 | The Hong Kong Polytechnic University | Cellulosic fabric with silk peptide/building block nanopolymer |
| MX2012003293A (en) | 2009-09-18 | 2012-04-30 | Procter & Gamble | Freshening compositions comprising malodor binding polymers and malodor counteractants. |
| US20120238942A1 (en) * | 2009-12-04 | 2012-09-20 | Michael Horstmann | Transdermal therapeutic System for the Administration of Peptides |
| WO2012131745A1 (en) | 2011-03-31 | 2012-10-04 | GIANIS S.r.L. | Binder and process for producing fabrics containing cyclodextrins fixed by said binder |
| WO2013147590A2 (en) | 2012-03-27 | 2013-10-03 | Essaidi Jalila | Method for treatment of spider silk-filament for use as thread or a composition in the manufacture of cosmetic, medical, textile or industrial applications such as bio-artificial cell tissue or artificial skin based on (recombinant) spider silk |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2780073B1 (en) * | 1998-06-19 | 2000-09-01 | Dim Sa | BIO-ACTIVE TEXTILE COMPRISING SILK PROTEIN AND ACTIVE PRODUCT MICROCAPSULES IN ITS FIBERS |
| EP2444549A1 (en) * | 2010-10-20 | 2012-04-25 | Stazione Sperimentale per la Seta | Textile materials with bioactive protection |
-
2014
- 2014-07-16 ES ES201431073A patent/ES2518765B2/en not_active Expired - Fee Related
-
2015
- 2015-04-21 WO PCT/ES2015/070328 patent/WO2016009095A1/en active Application Filing
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2005260A (en) | 1932-12-30 | 1935-06-18 | Atlas Powder Co | Press mechanism |
| ES2087996T3 (en) | 1990-01-18 | 1996-08-01 | Cpc International Inc | TEXTILE MATERIALS TREATMENT. |
| ES2245795T3 (en) | 1996-07-01 | 2006-01-16 | Unilever N.V. | DETERGENT COMPOSITION. |
| WO2003103550A2 (en) * | 2002-06-08 | 2003-12-18 | Ian Robert Thomson | Delivery system for a medicament or well-being enhancing composition |
| KR20040063730A (en) | 2003-01-08 | 2004-07-14 | 손영석 | Functional textile |
| KR20040064170A (en) | 2003-01-09 | 2004-07-16 | 손영석 | Functional cotton |
| DE10329685A1 (en) * | 2003-07-02 | 2005-01-20 | Cognis Deutschland Gmbh & Co. Kg | Microcapsules for use in detergents, rinsing or cleansing compositions or in production of pharmaceuticals, cosmetics or food supplements contain neurotransmitters or their precursors |
| EP1498113A1 (en) * | 2003-07-17 | 2005-01-19 | L'oreal | Use of beta-endorphin and/or agents with beta-endorphin-like activity in cosmetic and dermotology |
| US20080175991A1 (en) | 2007-01-22 | 2008-07-24 | The Hong Kong Polytechnic University | Cellulosic fabric with silk peptide/building block nanopolymer |
| MX2012003293A (en) | 2009-09-18 | 2012-04-30 | Procter & Gamble | Freshening compositions comprising malodor binding polymers and malodor counteractants. |
| US20120238942A1 (en) * | 2009-12-04 | 2012-09-20 | Michael Horstmann | Transdermal therapeutic System for the Administration of Peptides |
| WO2012131745A1 (en) | 2011-03-31 | 2012-10-04 | GIANIS S.r.L. | Binder and process for producing fabrics containing cyclodextrins fixed by said binder |
| WO2013147590A2 (en) | 2012-03-27 | 2013-10-03 | Essaidi Jalila | Method for treatment of spider silk-filament for use as thread or a composition in the manufacture of cosmetic, medical, textile or industrial applications such as bio-artificial cell tissue or artificial skin based on (recombinant) spider silk |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107641956A (en) * | 2017-09-08 | 2018-01-30 | 安徽龙盛纺织科技有限公司 | A kind of creped printing method of chiffon fabric |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2518765B2 (en) | 2015-03-05 |
| ES2518765A1 (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Cosmetotextiles: state of art | |
| ES2694430T3 (en) | Use of an article based on a polymer composition | |
| CN104294595A (en) | Production process for anti-bacterial deodorant textile | |
| CN105113075A (en) | Textile material | |
| Buschmann et al. | Medical, cosmetic and odour resistant finishes for textiles | |
| JP3022880B1 (en) | Clothing for promoting metabolism of stratum corneum and method for attaching microcapsules | |
| CN105177855A (en) | Nonwoven fabric specialized for copper ammonia fiber facial mask | |
| KR20080028214A (en) | Functional Persimmon Fabric and Fabrication Method | |
| WO2016009095A1 (en) | Functional textile fabrics | |
| Han et al. | Grafting cosmetic active ingredients for the functionalization of cosmetotextiles | |
| TWI279226B (en) | Dressings which can be applied several times to textile fibres and textile fabrics | |
| CN105708254B (en) | Both effectiveness magnetic therapy sleeping bag | |
| Chandrasekaran et al. | Analysis of eco-friendly medicinal herb extracts and essential oil applications on textile products for healthcare applications | |
| Jamal et al. | Cosmetotextiles: A wearable skin care | |
| CN107476066A (en) | A kind of antibiotic facing material of persistently delicate fragrance | |
| CN103767080A (en) | Warmth-keeping cotton underwear with function of skin care, function of health care and function of removing body odor of middle-aged and aged people and making method thereof | |
| CN109023930A (en) | A kind of heath-function material and its preparation method and application | |
| JP2003048264A (en) | Fiber structure | |
| CN204736497U (en) | Function fabric construction with keep apart bad smell | |
| JP2006152464A (en) | Fiber structure | |
| JP2002339252A (en) | Textile product for bedding | |
| CN206266760U (en) | A self-fragrant natural antibacterial and deodorant fiber | |
| KR102459187B1 (en) | Method for manufacturing textile paper impregnated with ascorbic acid and textiles containing ascorbic acid by its manufacturing method | |
| Dorugade et al. | Cosmetotextiles: A New Functionality of Garments for Well-Being | |
| KR100442013B1 (en) | Method for processing textile and/or textile goods by using nephrite water |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15729206 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/06/2017) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15729206 Country of ref document: EP Kind code of ref document: A1 |